Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity

International Journal of Cancer

Volumn 105, Issue 1, 2003, Pages 20-25

  Ahmed, Bisan ^a,b   Van Eijk, Loes I ^a   Bouma ter Steege, Jessica C A ^a   Van Der Schaft, Daisy W J ^a   Van Esch, Anita M ^a   Joosten Achjanie, Susan R ^a   Lambin, Philippe ^a,b   Landuyt, Willy ^b   Griffioen, Arjan W ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Dept of Experimental Radiobiology ^*  (Belgium)

Author keywords

Anti angiogenesis; Apoptosis; Combretastatin A4 phosphate; Endothelium; Migration

Indexed keywords

COMBRETASTATIN A4;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT; RHABDOMYOSARCOMA; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; RATS; STILBENES; TIME FACTORS; TUMOR CELLS, CULTURED; UMBILICAL VEINS; WOUND HEALING;

EID: 0037457666     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11010     Document Type: Article

References (33)

1. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases and chronic inflammation. Pharmacol Rev 2000;52:237-68.
2. Folkman J. Angiogenesis research: from laboratory to clinic. Forum 1999;9:59-62.
3. Denekamp J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993;66:181-96.
4. Chaplin DJ, Pettit GR, Parkins CS, Hill SA. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer 1996;27(Suppl):S86-8.
5. Auerbach W, Auerbach R. Angiogenesis inhibition: a review. Pharmacol Ther 1994;63:265-311.
6. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997;275:547-50.
7. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 1993;29A:1320-4.
8. Baguley BC, Zhuang L, Kestell P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Oncol Res 1997;9:55-60.
9. Hori K, Saito S, Nihei Y, Suzuki M, Sato Y. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 1999;90:1026-38.
10. Pettit GR, Cragg GM, Singh SB. Antineoplastic agents. 122. Constituents of Combretum caffrum. J Nat Prod 1987;50:386-91.
11. Iacobuzio-Donahue CA, Lee EL, Abraham SC, Yardley JH, Wu TT. Colchicine toxicity: distinct morphologic findings in gastrointestinal biopsies. Am J Surg Pathol 2001;25:1067-73.
12. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 1999;81:1318-27.
13. Pettit GR, Singh SB, Boyd MR, Hamel E, Pettit RK, Schmidt JM, Hogan F. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a). J Med Chem 1995;38:1666-72.
14. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:1829-34.
15. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999;59:1626-34.
16. Horsman MR, Murata R, Breidahl T, Nielsen FU, Maxwell RJ, Stodkiled-Jorgensen H, Overgaard J. Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv Exp Med Biol 2000;476:311-23.
17. Landuyt W, Verdoes O, Darius DO, Drijkoningen M, Nuyts S, Theys J, Stockx L, Wynendaele W, Fowler JF, Maleux G, Van den BW, Anne J, van Oosterom A, Lambin P. Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer 2000;36:1833-43.
18. Iyer S, Chaplin DJ, Rosenthal DS, Boulares AH, Li LY, Smulson ME. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 1998;58:4510-4.
19. Hamel E, Ho HH, Kang GJ, Lin CM. Cornigerine, a potent antimitotic Colchicum alkaloid of unusual structure. Interactions with tubulin. Biochem Pharmacol 1988;37:2445-9.
20. Nihei Y, Suzuki M, Okano A, Tsuji T, Akiyama Y, Tsuruo T, Saito S, Hori K, Sato Y. Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 1999;90:1387-95.
21. Beauregard DA, Hill SA, Chaplin DJ, Brindle KM. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 2001;61:6811-5.
22. Derhaag JG, Duijvestijn AM, Emeis JJ, Engels W, Breda Vriesman PJ. Production and characterization of spontaneous rat heart endothelial cell lines. Lab Invest 1996;74:437-51.
23. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-6.
24. Hotz MA, Gong J, Traganos F, Darzynkiewicz Z. Flow cytometric detection of apoptosis: comparison of the assays of in situ DNA degradation and chromatin changes. Cytometry 1994;15:237-44.
25. Van der Schaft DWJ, Toebes EAH, Haseman J, Mayo KH, Griffioen AW. Bactericidal permeability increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells. Blood 2000;96:176-81.
26. Hermens AF, Barendsen GW. Cellular proliferation patterns in an experimental rhabdomyosarcoma in the rat. Eur J Cancer 1967;3:361-9.
27. Hillen HF, Hak LE, Joosten-Achjanie SR, Arends JW. Microvessel density in unknown primary tumors. Int J Cancer 1997;74:81-5.
28. Griffioen AW, Van der Schaft DWJ, Barendsz-Janson AF, Cox A, Struijker Boudier HAJ, Hillen HFP, Mayo KH. Anginex, a designed peptide that inhibits angiogenesis. Biochem J 2001;2001:233-42.
29. Ohsumi K, Nakagawa R, Fukuda Y, Hatanaka T, Morinaga Y, Nihei Y, Ohishi K, Suga Y, Akiyama Y, Tsuji T. Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J Med Chem 1998;41:3022-32.
30. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, Barber PR, Vojnovic B, Chaplin DJ. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001;61:6413-22.
31. el Zayat AA. Degen D, Drabek S, Clark GM, Pettit GR, Von Hoff DD. In vitro evaluation of the antineoplastic activity of combretastatin A- 4, a natural product from Combretum caffrum (arid shrub). Anticancer Drugs 1993;4:19-25.
32. Nabha SM, Mohammad RM, Dandashi MH, Coupaye-Gerard B, Aboukameel A, Pettit GR, Al Katib AM. Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clin Cancer Res 2002;8:2735-41.
33. Kusaka M, Sudo K, Matsutani E, Kozai Y, Marui S, Fujita T, Ingber D, Folkman J. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994;69:212-6.